Wockhardt Contract Services

Article

Thanks to expert staff, Wockhardt has become a leading global Pharmaceutical Contract Manufacturer. From development to high-volume commercial manufacture, we utilise more than 25 years of contract manufacturing experience to ensure your product is professionally managed all the way to market.

Lyophilisation I Sterile injectables I Solid Dose I Liquids I Ointments I Creams I Powders I Specialised products

Meet the Wockhardt team …… your project is safe in our hands

Thanks to expert staff, Wockhardt has become a leading global Pharmaceutical Contract Manufacturer. From development to high-volume commercial manufacture, we utilise more than 25 years of contract manufacturing experience to ensure your product is professionally managed all the way to market.

We offer a “Full Turnkey” value-added service from API production and product development through to scale-up with global options to maintain a competitive advantage. With a network of 12 facilities located throughout the US, Europe and Asia we aim to provide our cost-effective services where and when you need them. From biotechnology to leading global pharmaceutical companies, Wockhardt is ideally placed to meet your needs.

Our flexible, end-to-end service is redefining manufacture for a range of sterile injectables and other dosage forms.Wockhardt gets results fast. From initial agreement to production, our average time to completion of technology transfer is just 4 months. We’ve even completed some programmes within just 2.

Our staff are experts in their own fields and they are dedicated to providing you with extraordinary service every day. Just think, what could the Wockhardt team achieve for you?

Wockhardt – Delivering Extraordinary Service Everyday

Contact details for publishing
Head of Contract Manufacturing Services
Tel: +44 (0)1978 669358
E-mail: knowhow@wockhardt.com
Web address: www.wockhardt-knowhow.com

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content